Reinterpreting the Fate of Iridium(III) Photocatalysts─Screening a Combinatorial Library to Explore Light-Driven Side-Reactions.

Photoredox catalysts are primarily selected based on ground and excited state properties, but their activity is also intrinsically tied to the nature of their reduced (or oxidized) intermediates. Catalyst reactivity often necessitates an inherent instability, thus these intermediates represent a mechanistic turning point that affords either product formation or side-reactions. In this work, we explore the scope of a previously demonstrated side-reaction that partially saturates one pyridine ring of the ancillary ligand in heteroleptic iridium(III) complexes. Using high-throughput synthesis and screening under photochemical conditions, we identified different chemical pathways, ultimately governed by ligand composition. The ancillary ligand was the key factor that determined photochemical stability. Following photoinitiated electron transfer from a sacrificial tertiary amine, the reduced intermediate of complexes containing 1,10-phenanthroline derivatives exhibited long-term stability. In contrast, complexes containing 2,2'-bipyridines were highly susceptible to hydrogen atom transfer and ancillary ligand modification. Detailed characterization of selected complexes before and after transformation showed differing effects on the ground and excited state reduction potentials dependent on the nature of the cyclometalating ligands and excited states. The implications of catalyst stability and reactivity in chemical synthesis was demonstrated in a model photoredox reaction.

Examining the Role of Aryldiazonium Salts in Surface Electroinitiated Polymerization.

Historically, the irreversible reduction of aryldiazonium salts has provided a reliable method to modify surfaces, demonstrating a catalogue of suitable diazonium salts for targeted applications. This work expands the knowledge of diazonium salt chemistry to participate in surface electroinitiated emulsion polymerization (SEEP). The influence of concentration, electronic effects, and steric hindrance/regiochemistry of the diazonium salt initiator on the production of polymeric films is examined. The objective of this work is to determine if a polymer film can be tailored, controlling the thickness, density, and surface homogeneity using specific diazonium chemistry. The data presented herein demonstrate a significant difference in polymer films that can be achieved when selecting a variety of diazonium salts and vinylic monomers. A clear trend aligns with the electron-rich diazonium salt substitution providing the thickest films (up to 70.9 ± 17.8 nm) with increasing diazonium concentration and electron-withdrawing substitution achieving optimal homogeneity for the surface of the film at a 5 mM diazonium concentration.

Copper Bis(thiosemicarbazonato)-stilbenyl Complexes That Bind to Amyloid-ß Plaques.

Alzheimer's disease is characterized by the presence of extracellular amyloid-ß plaques. Positron emission tomography (PET) imaging with tracers radiolabeled with positron-emitting radionuclides that bind to amyloid-ß plaques can assist in the diagnosis of Alzheimer's disease. With the goal of designing new imaging agents radiolabeled with positron-emitting copper-64 radionuclides that bind to amyloid-ß plaques, a family of bis(thiosemicarbazone) ligands with appended substituted stilbenyl functional groups has been prepared. The ligands form charge-neutral and stable complexes with copper(II). The new ligands can be radiolabeled with copper-64 at room temperature. Two lead complexes were demonstrated to bind to amyloid-ß plaques present in post-mortem brain tissue from subjects with clinically diagnosed Alzheimer's disease and crossed the blood-brain barrier in mice. The work presented here provides strategies to prepare compounds with radionuclides of copper that can be used for targeted brain PET imaging.

The Tandem Photoredox Catalysis Mechanism of [Ir(ppy)2(dtb-bpy)]+ Enabling Access to Energy Demanding Organic Substrates.

We report the discovery of a tandem catalytic process to reduce energy demanding substrates, using the [Ir(ppy)2(dtb-bpy)]+ (1+) photocatalyst. The immediate products of photoinitiated electron transfer (PET) between 1+ and triethylamine (TEA) undergo subsequent reactions to generate a previously unknown, highly reducing species (2). Formation of 2 occurs via reduction and semisaturation of the ancillary dtb-bpy ligand, where the TEA radical cation serves as an effective hydrogen atom donor, confirmed by nuclear magnetic resonance, mass spectrometry, and deuterium labeling experiments. Steady-state and time-resolved luminescence and absorption studies reveal that upon irradiation, 2 undergoes electron transfer or proton-coupled electron transfer (PCET) with a representative acceptor (N-(diphenylmethylene)-1-phenylmethanamine; S). Turnover of this new photocatalytic cycle occurs along with the reformation of 1+. We rationalize our observations by proposing the first example of a mechanistic pathway where two distinct yet interconnected photoredox cycles provide access to an extended reduction potential window capable of engaging a wide range of energy demanding and synthetically relevant organic substrates including aryl halides.

Mixed annihilation electrogenerated chemiluminescence of iridium(iii) complexes.

Previously reported annihilation ECL of mixtures of metal complexes have generally comprised Ir(ppy)3 or a close analogue as a higher energy donor/emitter (green/blue light) and [Ru(bpy)3]2+ or its derivative as a lower energy acceptor/emitter (red light). In contrast, here we examine Ir(ppy)3 as the lower energy acceptor/emitter, by combining it with a second Ir(iii) complex: [Ir(df-ppy)2(ptb)]+ (where ptb = 1-benzyl-1,2,3-triazol-4-ylpyridine). The application of potentials sufficient to attain the first single-electron oxidation and reduction products can be exploited to detect Ir(ppy)3 at orders of magnitude lower concentration, or enhance its maximum emission intensity at high concentration far beyond that achievable through conventional annihilation ECL of Ir(ppy)3 involving comproportionation. Moreover, under certain conditions, the colour of the emission can be selected through the applied electrochemical potentials. We have also prepared a novel Ir(iii) complex with a sufficiently low reduction potential that the reaction between its reduced form and Ir(ppy)3+ cannot populate the excited state of either luminophore. This enabled, for the first time, the exclusive formation of either excited state through the application of higher cathodic or anodic potentials, but in both cases, the ECL was greatly diminished by parasitic dark reactions.

Synthesis of Oxorhenium(V) and Oxotechnetium(V) Complexes That Bind to Amyloid-ß Plaques.

Alzheimer's disease is characterized by the presence of amyloid plaques in the brain. The primary constituents of the plaques are aggregated forms of the amyloid-ß (Aß) peptide. With the goal of preparing technetium-99(m) complexes that bind to Aß plaques with the potential to be diagnostic imaging agents for Alzheimer's disease, new tetradentate ligands capable of forming neutral and lipophilic complexes with oxotechentium(V) and oxorhenium(V) were prepared. Nonradioactive isotopes of technetium are not available so rhenium was used as a surrogate for exploratory chemistry. Two planar tetradentate N3O ligands were prepared that form charge-neutral complexes with oxorhenium(v) as well as a ligand featuring a styrylpyridyl functional group designed to bind to Aß plaques. All three ligands formed complexes with oxorhenium(V), and each complex was characterized by NMR spectroscopy, mass spectrometry, and X-ray crystallography. The oxorhenium(V) complex with a styrylpyridyl functional group binds to Aß plaques present in post-mortem human brain tissue. The chemistry was extrapolated to technetium-99(m) at the tracer level for two of the ligands. The resulting oxotechnetium(V) complexes were sufficiently lipophilic and charge-neutral to suggest that they have the potential to cross the blood-brain barrier but exhibited modest stability with respect to exchange with histidine. The chemistry presented here identifies a strategy to integrate styrylpyridyl functional groups into tetradentate ligands capable of forming complexes with [M═O](3+) cores (M = Re or Tc).

Toward hypoxia-selective rhenium and technetium tricarbonyl complexes.

With the aim of preparing hypoxia-selective imaging and therapeutic agents, technetium(I) and rhenium(I) tricarbonyl complexes with pyridylhydrazone, dipyridylamine, and pyridylaminocarboxylate ligands containing nitrobenzyl or nitroimidazole functional groups have been prepared. The rhenium tricarbonyl complexes were synthesized with short reaction times using microwave irradiation. Rhenium tricarbonyl complexes with deprotonated p-nitrophenyl pyridylhydrazone ligands are luminescent, and this has been used to track their uptake in HeLa cells using confocal fluorescent microscopy. Selected rhenium tricarbonyl complexes displayed higher uptake in hypoxic cells when compared to normoxic cells. A (99m)Tc tricarbonyl complex with a dipyridylamine ligand bearing a nitroimidazole functional group is stable in human serum and was shown to localize in a human renal cell carcinoma (RCC; SK-RC-52) tumor in a mouse.

Metal complexes designed to bind to amyloid-ß for the diagnosis and treatment of Alzheimer's disease.

Alzheimer's disease is the most common form of age-related neurodegenerative dementia. The disease is characterised by the presence of plaques in the cerebral cortex. The major constituent of these plaques is aggregated amyloid-ß peptide. This review focuses on the molecular aspects of metal complexes designed to bind to amyloid-ß. The development of radioactive metal-based complexes of copper and technetium designed as diagnostic imaging agents to detect amyloid burden in the brain is discussed. Separate sections of the review discuss the use of luminescent metal complexes to act as non-conventional probes of amyloid formation and recent research into the use of metal complexes as inhibitors of amyloid formation and toxicity.

Rhenium and technetium tricarbonyl complexes of 1,4-Substituted pyridyl-1,2,3-triazole bidentate 'click' ligands conjugated to a targeting RGD peptide.

New 1,4-substituted pyridyl-1,2,3-triazole ligands with pendent phenyl isothiocyanate functional groups linked to the heterocycle through a short methylene or longer polyethylene glycol spacers were prepared and conjugated to a peptide containing the arginine-glycine-aspartic acid peptide motif. Rhenium and technetium carbonyl complexes, [M(CO)3 L(x) (py)](+) (where M = Re(I) or (99m) Tc(I) ; L(x) = 1,4-substituted pyridyl-1,2,3-triazole ligands and py = pyridine) were prepared. One rhenium complex has been characterized by X-ray crystallography, and the luminescent properties of [M(CO)3 L(x) (py)](+) are reported.

Redox-mediated electrochemiluminescence enhancement for bead-based immunoassay.

Electrochemiluminescence (ECL) is a highly sensitive mode of detection utilised in commercialised bead-based immunoassays. Recently, the introduction of a freely diffusing water-soluble Ir(iii) complex was demonstrated to enhance the ECL emission of [Ru(bpy)3]2+ labels anchored to microbeads, but a comprehensive investigation of the proposed 'redox-mediated' mechanism was not carried out. In this work, we select three different water-soluble Ir(iii) complexes by virtue of their photophysical and electrochemical properties in comparison with those of the [Ru(bpy)3]2+ luminophore and the TPrA co-reactant. A systematic investigation of the influence of each Ir(iii) complex on the emission of the Ru(ii) labels on single beads by ECL microscopy revealed that the heterogeneous ECL can be finely tuned and either enhanced up to 107% or lowered by 75%. The variation of the [Ru(bpy)3]2+ ECL emission was correlated to the properties of each Ir(iii)-based mediator, which enabled us to decipher the mechanism of interaction and define guidelines for the future design of novel Ir(iii) complexes to further enhance the ECL emission of bead-based immunoassays. Ultimately, we showcase the potential of this technology for practical sample analysis in commercial instruments by assessing the enhancement of the collective ECL intensity from a bead-based system.

Chemiluminescence and electrochemiluminescence of water-soluble iridium(III) complexes containing a tetraethylene-glycol functionalised triazolylpyridine ligand.

BACKGROUND: Iridium(III) complexes, exhibiting high luminescence quantum yields and a wide range of emission colours, are promising alternatives to tris(2,2'-bipyridine)ruthenium(II) for chemiluminescence (CL) and electrochemiluminescence (ECL) detection. This emerging class of reagent, however, is limited by the poor solubility of many iridium(III) complexes in aqueous solution, and lack of understanding of their remarkably variable selectivities towards different analytes. RESULTS: Seven [Ir(C^N)2(pt-TEG)]+ complexes, exhibiting a wide range of reduction potentials and emission energies, were examined with six model analytes. For CL, cerium(IV) was used as the oxidant. The alkylamine analytes generally produced greater CL and ECL with the more readily oxidised Ir(III) complexes (C^N = piq, bt, ppy), predominantly through the 'direct' pathway requiring oxidation of both metal complex and analyte. Aniline derivatives that did not also contain secondary or tertiary alkylamines elicited CL from the less readily oxidised complexes (C^N = df-ppy-CF3, df-ppy) via energy transfer. The most difficult to oxidise complexes (C^N = df(CF3)-ppy-Me, df(CN)-ppy) gave poor responses due to the limited potential window of the solvent and inefficiency of energy transfer to their high energy excited states. Greater CL and/or ECL intensities were generally obtained for each analyte with at least one Ir(III) complex than with [Ru(bpy)3]2+; superior limits of detection for two analytes were demonstrated. SIGNIFICANCE: This exploration of CL/ECL in which the properties of luminophore, analyte and oxidant are all varied provides a new understanding of the influence of the metal-complex potentials and excited state energy on the light-producing and quenching pathways, and consequently, their distinct selectivity towards different analytes. These findings will guide the development of water-soluble Ir(III) complexes as CL and ECL reagents.

Diagnostic imaging agents for Alzheimer's disease: copper radiopharmaceuticals that target Aß plaques.

One of the pathological hallmarks of Alzheimer's disease is the presence of amyloid-ß plaques in the brain and the major constituent of these plaques is aggregated amyloid-ß peptide. New thiosemicarbazone-pyridylhydrazine based ligands that incorporate functional groups designed to bind amyloid-ß plaques have been synthesized. The new ligands form stable four coordinate complexes with a positron-emitting radioactive isotope of copper, (64)Cu. Two of the new Cu(II) complexes include a functionalized styrylpyridine group and these complexes bind to amyloid-ß plaques in samples of post-mortem human brain tissue. Strategies to increase brain uptake by functional group manipulation have led to a (64)Cu complex that effectively crosses the blood-brain barrier in wild-type mice. The new complexes described in this manuscript provide insight into strategies to deliver metal complexes to amyloid-ß plaques.

Carbon fibre surface modification facilitated by silver-catalysed radical decarboxylation.

A silver catalysed radical decarboxylation process was used to graft a copolymer (4 : 1; methylacrylate/acrylic acid) onto short carbon fibres. Surface grafting was confirmed by XPS, SEM and TGA, suggesting that the polymer accounted for 10% of the modified materials mass. Incorporation of these surface enhanced carbon fibres into an epoxy resin gave composites demonstrating an increase in ductility and a clear change in failure mode from adhesive, at the fibre-matrix interface, to cohesive, within the matrix polymer itself.

Carbon Fiber Surface Functional Landscapes: Nanoscale Topography and Property Distribution.

The ultimate properties of carbon fibers and their composites are largely dictated by the surface topography of the fibers and the interface characteristics, which are primarily influenced by the surface distribution of chemical functionalities and their interactions with the matrix resin. Nevertheless, nanoscale insights on the carbon fiber surface in relationship with its chemical modification are still rarely addressed. Here, we demonstrate a critical insight on the nanoscale surface topography characterization of modified novel carbon fibers using high-resolution atomic force microscopy at multiple length scales. We compare the nanoscale surface characteristics relevant to their role in controlling interfacial interactions for carbon fibers manufactured at two different tensions and two distinct chemically functionalized coatings. We used surface dimple (also known as nanopores) profiling, microroughness analysis, power spectral density analysis, and adhesion and electrostatic potential mapping to reveal the fine details of surface characteristics at different length scales. This analysis demonstrates that the carbon fibers processed at lower tension possess a higher fractal dimension with a more corrugated surface and higher surface roughness, which leads to increased surface adhesion and energy dissipation across nano- and microscales. Furthermore, electrochemical surface modification with amine- and fluoro-functional groups significantly masks the microroughness inherent to these fibers. This results in increased fractal dimension and decreased energy dissipation and adhesion due to the high chemical reactivity in the areas of asperities and surface defects combined with a significant increase in the surface potential, as revealed by Kelvin probe mapping. These local surface properties of carbon fibers are crucial for designing next-generation fiber composites with predictable interfacial strength and the overall mechanical performance by considering the fiber surface topography for proper control of interphase formation.

A simple, low-cost instrument for electrochemiluminescence immunoassays based on a Raspberry Pi and screen-printed electrodes.

A powerful, yet low-cost and semi-portable electrochemiluminescence (ECL) biosensing device is described. It is constructed around a Raspberry Pi single-board computer, which serves as the controller and user interface. The Pi is interfaced with an expansion board that controls the potential applied to a disposable screen-printed electrode and facilitates data acquisition from a photomultiplier tube (PMT), which detects the ECL emission from the sensor surface. As proof-of-concept, we demonstrate that this arrangement can quantitate tris(2,2'-bipyridine)ruthenium(II) ([Ru(bpy)3]2+]) with an estimated limit of detection (LOD) of 20 pM, and C-reactive protein with an LOD of 50 fg mL-1. The analytical performance of the Raspberry Pi-based setup is comparable to a conventional ECL configuration (computer, potentiostat and photodetector). The Raspberry Pi-based setup can replace a conventional ECL setup, at a fraction of the cost, without sacrificing sensitivity or versatility. The combination of a single-board computer and a sensitive light detector represents a significant step towards translating ECL instruments into mobile, point-of-care diagnostic platforms.

A redox-mediator pathway for enhanced multi-colour electrochemiluminescence in aqueous solution.

The classic and most widely used co-reactant electrochemiluminescence (ECL) reaction of tris(2,2'-bipyridine)ruthenium(ii) ([Ru(bpy)3]2+) and tri-n-propylamine is enhanced by an order of magnitude by fac-[Ir(sppy)3]3- (where sppy = 5'-sulfo-2-phenylpyridinato-C 2,N), through a novel 'redox mediator' pathway. Moreover, the concomitant green emission of [Ir(sppy)3]3-* enables internal standardisation of the co-reactant ECL of [Ru(bpy)3]2+. This can be applied using a digital camera as the photodetector by exploiting the ratio of R and B values of the RGB colour data, providing superior sensitivity and precision for the development of low-cost, portable ECL-based analytical devices.

Self-enhanced multicolor electrochemiluminescence by competitive electron-transfer processes.

Controlling electrochemiluminescence (ECL) color(s) is crucial for many applications ranging from multiplexed bioassays to ECL microscopy. This can only be achieved through the fundamental understanding of high-energy electron-transfer processes in complex and competitive reaction schemes. Recently, this field has generated huge interest, but the effective implementation of multicolor ECL is constrained by the limited number of ECL-active organometallic dyes. Herein, the first self-enhanced organic ECL dye, a chiral red-emitting cationic diaza [4]helicene connected to a dimethylamino moiety by a short linker, is reported. This molecular system integrates bifunctional ECL features (i.e. luminophore and coreactant) and each function may be operated either separately or simultaneously. This unique level of control is enabled by integrating but decoupling both molecular functions in a single molecule. Through this dual molecular reactivity, concomitant multicolor ECL emission from red to blue with tunable intensity is readily obtained in aqueous media. This is done through competitive electron-transfer processes between the helicene and a ruthenium or iridium dye. The reported approach provides a general methodology to extend to other coreactant/luminophore systems, opening enticing perspectives for spectrally distinct detection of several analytes, and original analytical and imaging strategies.

Water-Soluble Iridium(III) Complexes Containing Tetraethylene-Glycol-Derivatized Bipyridine Ligands for Electrogenerated Chemiluminescence Detection.

Four cationic heteroleptic iridium(III) complexes containing a 2,2'-bipyridine (bpy) ligand with one or two tetraethylene glycol (TEG) groups attached in the 4 or 4,4' positions were synthesized to create new water-soluble electrogenerated chemiluminescence (ECL) luminophores bearing a convenient point of attachment for the development of ECL-labels. The novel TEG-derivatized bipyridines were incorporated into [Ir(C∧N)2(R-bpy-R')]Cl complexes, where C∧N = 2-phenylpyridine anion (ppy) or 2-phenylbenzo[d]thiazole anion (bt), through reaction with commercially available ([Ir(C∧N)2(µ-Cl)]2 dimers. The novel [Ir(C∧N)2(Me-bpy-TEG)]Cl and [Ir(C∧N)2(TEG-bpy-TEG)]Cl complexes in aqueous solution largely retained the redox potentials and emission spectra of the parent [Ir(C∧N)2(Me-bpy-Me)]PF6 (where Me-bpy-Me = 4,4'methyl-2,2'-bipyridine) luminophores in acetonitrile, and exhibited ECL intensities similar to those of [Ru(bpy)3]2+ and the analogous [Ir(C∧N)2(pt-TEG]Cl complexes (where pt-TEG = 1-(TEG)-4-(2-pyridyl)-1,2,3-triazole). These complexes can be readily adapted for bioconjugation and considering the spectral distributions of [Ir(ppy)2(Me-bpy-TEG)]+ and [Ir(ppy)2(pt-TEG)]+, show a viable strategy to create ECL-labels with different emission colors from the same commercial [Ir(ppy)2(µ-Cl)]2 precursor.

A conceptual framework for the development of iridium(iii) complex-based electrogenerated chemiluminescence labels.

Translation of the highly promising electrogenerated chemiluminescence (ECL) properties of Ir(iii) complexes (with tri-n-propylamine (TPrA) as a co-reactant) into a new generation of ECL labels for ligand binding assays necessitates the introduction of functionality suitable for bioconjugation. Modification of the ligands, however, can affect not only the photophysical and electrochemical properties of the complex, but also the reaction pathways available to generate light. Through a combined theoretical and experimental study, we reveal the limitations of conventional approaches to the design of electrochemiluminophores and introduce a new class of ECL label, [Ir(C^N)2(pt-TOxT-Sq)]+ (where C^N is a range of possible cyclometalating ligands, and pt-TOxT-Sq is a pyridyltriazole ligand with trioxatridecane chain and squarate amide ethyl ester), which outperformed commercial Ir(iii) complex labels in two commonly used assay formats. Predicted limits on the redox potentials and emission wavelengths of Ir(iii) complexes capable of generating ECL via the dominant pathway applicable in microbead supported ECL assays were experimentally verified by measuring the ECL intensities of the parent luminophores at different applied potentials, and comparing the ECL responses for the corresponding labels under assay conditions. This study provides a framework to tailor ECL labels for specific assay conditions and a fundamental understanding of the ECL pathways that will underpin exploration of new luminophores and co-reactants.

Modulating Protein Phosphatase 2A Rescues Disease Phenotype in Neurodegenerative Tauopathies.

Alzheimer's disease (AD) is the leading cause of dementia worldwide accounting for around 70% of all cases. There is currently no treatment for AD beyond symptom management and attempts at developing disease-modifying therapies have yielded very little. These strategies have traditionally targeted the peptide Aß, which is thought to drive pathology. However, the lack of clinical translation of these Aß-centric strategies underscores the need for diverse treatment strategies targeting other aspects of the disease. Metal dyshomeostasis is a common feature of several neurodegenerative diseases such as AD, Parkinson's disease, and frontotemporal dementia, and manipulation of metal homeostasis has been explored as a potential therapeutic avenue for these diseases. The copper ionophore glyoxalbis-[N4-methylthiosemicarbazonato]Cu(II) (CuII(gtsm)) has previously been shown to improve the cognitive deficits seen in an AD animal model; however, the molecular mechanism remained unclear. Here we report that the treatment of two animal tauopathy models (APP/PS1 and rTg4510) with CuII(gtsm) recovers the cognitive deficits seen in both neurodegenerative models. In both models, markers of tau pathology were significantly reduced with CuII(gtsm) treatment, and in the APP/PS1 model, the levels of Aß remained unchanged. Analysis of tau kinases (GSK3ß and CDK5) revealed no drug induced changes; however, both models exhibited a significant increase in the levels of the structural subunit of the tau phosphatase, PP2A. These findings suggest that targeting the tau phosphatase PP2A has therapeutic potential for preventing memory impairments and reducing the tau pathology seen in AD and other tauopathies.